New Epigenetic Reader Domain Inhibitors
| Cat.No. | Product Name | Information |
|---|---|---|
| S8723 | ABBV-744 | ABBV-744 is a BDII-selective BET bromodomain inhibitor that inhibits BRD2, BRD3 and BRD4. It is developed for treating AML and cancers. |
| S8409 | KG-501 (2-naphthol-AS-E-phosphate) | KG-501 is a cAMP response element-binding protein (CREB) inhibitor that disrupts CREB-dependent transcription (Ki = 10 μM) and CREB:CBP interaction (Ki = 50 μM). It also disrupts phospho (Ser-133) CREB binding to KIX with a Ki of ≈90 μM, using concentrations of CREB that were within the linear range of the binding assay. |
| ≡ All Epigenetic Reader Domain Inhibitors | ||
